{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:31:13Z","timestamp":1649165473599},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.ijcard.2004.07.018","type":"journal-article","created":{"date-parts":[[2005,2,27]],"date-time":"2005-02-27T00:44:46Z","timestamp":1109465086000},"page":"235-237","source":"Crossref","is-referenced-by-count":0,"title":["REVERSAL and PROVE-IT: Are clinically oriented trials really better than \u201cpure\u201d scientific studies?"],"prefix":"10.1016","volume":"103","author":[{"given":"A.F.G.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gaddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ijcard.2004.07.018_bib1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2004.07.018_bib2","first-page":"350","article-title":"Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2004.07.018_bib3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijcard.2004.07.018_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2003.08.001","article-title":"Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients","volume":"94","author":"Sakabe","year":"2004","journal-title":"Int. J. Cardiol."},{"issue":"17","key":"10.1016\/j.ijcard.2004.07.018_bib5","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.CIR.0000066320.27195.B4","article-title":"Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among U.S. adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000","volume":"107","author":"Ford","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2004.07.018_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(03)14234-1","article-title":"Dyslipidaemia","volume":"362","author":"Durrington","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijcard.2004.07.018_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2796.2003.01276.x","article-title":"Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy","volume":"255","author":"Walldius","year":"2004","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2004.07.018_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1381612043453388","article-title":"Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the risk-benefit profile","volume":"10","author":"Napoli","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"19","key":"10.1016\/j.ijcard.2004.07.018_bib9","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/archinte.163.19.2306","article-title":"Peripheral arterial disease: identification and implications","volume":"163","author":"Mohler","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"9364","key":"10.1016\/j.ijcard.2004.07.018_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9261","key":"10.1016\/j.ijcard.2004.07.018_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(00)04235-5","article-title":"Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II group. European action on secondary prevention by intervention to reduce events","volume":"357","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijcard.2004.07.018_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0091270004263016","article-title":"Clinical trials and lipid guidelines for type II diabetes","volume":"44","author":"Prisant","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2004.07.018_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1026132412074","article-title":"The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk","volume":"17","author":"Corsini","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.ijcard.2004.07.018_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5551\/jat.10.25","article-title":"Preventing angiographic progression of coronary atherosclerosis with pravastatin","volume":"10","author":"Daida","year":"2003","journal-title":"J. Atheroscler. Thromb."},{"issue":"1 Suppl 1","key":"10.1016\/j.ijcard.2004.07.018_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/clc.4960261306","article-title":"Comparing HMG-CoA reductase inhibitors","volume":"26","author":"Jones","year":"2003","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2004.07.018_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial","volume":"360","year":"2002","journal-title":"Lancet"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527305000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527305000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T12:29:27Z","timestamp":1548678567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527305000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0167527305000598"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2004.07.018","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}